ArticleClinical research in cardiology : official journal of the German Cardiac Society2011
Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04632719 (MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19), which is not on this map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.European heart journal · 2023Pooled it
- Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.Clinical cardiology · 2017Trial
- Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2017Trial
- Does self-management counseling in patients with heart failure improve quality of life? Findings from the Heart Failure Adherence and Retention Trial (HART).Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2014Trial
- Physical rehabilitation for older patients with acute HFpEF (REHAB-HFpEF) trial: Design and rationale.American heart journal · 2026Article
- Effects of exercises based on ACSM recommendations on patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.Frontiers in physiology · 2026Review
- Prevalence of Comorbidity and Associated Factors Among Patients With Hypertension in Health Facilities of Southern Ethiopia.BioMed research international · 2026Article
- Differential Associations of Cardiac, Pulmonary, Arterial, and Muscle Physiological Parameters and Biomarkers With the Incidence of HFpEF and HFrEF.JACC. Heart failure · 2025Article
- ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure.Current hypertension reports · 2024Review
- Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease.Biomedicines · 2024Review
- Heart Failure with Preserved Left Ventricular Ejection Fraction: A Complex Conundrum Simply Not Limited to Diastolic Dysfunction.Cardiovascular therapeutics · 2023Review
- Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.European journal of heart failure · 2022Article
- Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives.Journal of geriatric cardiology : JGC · 2021Article
- Overview of the socio-economic consequences of heart failure.Cardiovascular diagnosis and therapy · 2021Review
- Recurrent Admissions for Acute Decompensated Heart Failure Among Patients With and Without Peripheral Artery Disease: The ARIC Study.Journal of the American Heart Association · 2020Article
- Clinical Predictors Influencing the Length of Stay in Emergency Department Patients Presenting with Acute Heart Failure.Medicina (Kaunas, Lithuania) · 2020Article
- Article
- Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction.Open heart · 2020Observational
- Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.American journal of cardiovascular disease · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComorbidities negatively affect prognosis more strongly in heart failure with preserved (HFpEF) than with reduced (HFrEF) ejection fraction. Their comparative impact on physical impairment in HFpEF and HFrEF has not been evaluated so far. METHODS AND
resultsThe frequency of 12 comorbidities and their impact on NYHA class and SF-36 physical functioning score (SF-36 PF) were evaluated in 1,294 patients with HFpEF and 2,785 with HFrEF. HFpEF patients had lower NYHA class (2.0 ± 0.6 vs. 2.4 ± 0.6, p < 0.001) and higher SF-36 PF score (54.4 ± 28.3 vs. 54.4 ± 27.7, p < 0.001). All comorbidities were significantly (p < 0.05) more frequent in HFrEF, except hypertension and obesity, which were more frequent in HFpEF (p < 0.001). Adjusting for age and gender, COPD, anemia, hyperuricemia, atrial fibrillation, renal dysfunction, cerebrovascular disease and diabetes had a similar (p for interaction > 0.05) negative effect in both groups. Obesity, coronary artery disease and peripheral arterial occlusive disease exerted a significantly (p < 0.05) more adverse effect in HFpEF, while hypertension and hyperlipidemia were associated with fewer (p < 0.05) symptoms in HFrEF only. The total impact of comorbidities on NYHA (AUC for prediction of NYHA III/IV vs. I/II) and SF-36 PF (r(2)) in multivariate analyses was approximately 1.5-fold higher in HFpEF, and also much stronger than the impact of a 10% decrease in ejection fraction in HFrEF or a 5 mm decrease in left ventricular end-diastolic diameter in HFpEF.
conclusionThe impact of comorbidities on physical impairment is higher in HFpEF than in HFrEF. This should be considered in the differential diagnosis and in the treatment of patients with HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.